Business
Medicenna Announces Filing of Final Short Form Prospectus
Medicenna Announces Filing of Final Short Form Prospectus Canada NewsWire TORONT...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Filing of Final Short Form Prospectus\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Oct. 11, 2019\n\n\n\n/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./\n TORONTO and HOUSTON, Oct. 11, 2019 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has filed a (final) short form prospectus (the \"Prospectus\") which has been receipted by the regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario, in connection with the marketed offering (the \"Offering\") of units of the Company (\"Units\"). A copy of the Prospectus is available under the Company's profile at www.sedar.com.\nPursuant to the Offering, the Company intends to issue a minimum of 3,076,924 Units and a maximum of 4,615,386 Units at a price of CDN$1.30 per Unit for minimum gross proceeds of CDN$4,000,001 and maximum gross proceeds of CDN$6,000,002. Each Unit is comprised of one common share of the Company (a \"Common Share\") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a \"Warrant\"). Each Warrant entitles the holder thereof to acquire one Common Share (a \"Warrant Share\") at an exercise price of CDN$1.75 per Warrant Share for a period of 36 months following the closing of the Offering.\nThe Offering is undertaken on a best efforts basis pursuant to the terms and conditions of an agency agreement (the \"Agency Agreement\") entered into between Bloom Burton Securities Inc., Mackie Research Capital Corporation, Haywood Securities Inc. (collectively, the \"Agents\") and the Company. In connection with the Offering, the Agents will be paid a cash commission equal to 7.0% of the aggregate gross proceeds of the Offering and will be issued compensation options exercisable to acquire such number of Common Shares as is equal to 7.0% of the aggregate number of Uni...